

Product Data Sheet

PRAMEF9 siRNA (Human)

Catalog # Source Reactivity Applications CRJ7423 Synt+ic H RNAi Description siRNA to inhibit PRAMEF9 expression using RNA interference Specificity PRAMEF9 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression. Form Lyophilized powder Veryphilized powder Gene Symbol PRAMEF9 PRAMEF9 Alternative N=me PRAMEF9 Veryphilized powder SwissProt QSVWM5 (Human) Veryphilized powder SwissProt QSVWM5 (Human) Veryphilized powder Quality Control QSVWM5 (Human) Veryphilized powder Quality Control QSVWT5 (Human) Veryphilized powder Quality Control QSVWT5 (Human) Veryphilized powder Quality Control Oligo== coupling efficiency. The oligo by base through trityl analysis to ensure appropriate coupling efficiency. The oligo by base through trityl analysis to ensure propriate coupling efficiency. The oligo is further analyzed by mass Quality Control Veryphilized powder is further analyzed by mass Components We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of
DescriptionsiRNA to inhibit PRAMEF9 expression using RNA interferenceSpecificityPRAMEF9 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.FormLyophilized powderGene SymbolPRAMEF9Alternative NamesPRAME family member 9Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
SpecificityPRAMEF9 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.FormLyophilized powderGene SymbolPRAMEF9Alternative NamesPRAME family member 9Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
to knock down gene expression.FormLyophilized powderGene SymbolPRAMEF9Alternative NamesPRAME family member 9Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
FormLyophilized powderGene SymbolPRAMEF9Alternative NamesPRAME family member 9Alternative Names343070 (Human)Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Gene SymbolPRAMEF9Alternative NamesPRAME family member 9Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Alternative NamesPRAME family member 9Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Entrez Gene343070 (Human)SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
SwissProtQ5VWM5 (Human)Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Purity> 97%Quality ControlOligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Quality Control Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Components We offers pre-designed sets of 3 different target-specific siRNA oligo duplexes of
human PRAMEF9 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes
can be transfected individually or pooled together to achieve knockdown of the
target gene, which is most commonly assessed by qPCR or western blot.
Component 15 nmol 30 nmol
PRAMEF9 siRNA (Human) - A 5 nmol x 1 5 nmol x 2
PRAMEF9 siRNA (Human) - B 5 nmol x 1 5 nmol x 2

Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC-Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb-Rabbit, S- Sheep, Z- Zebrafish

COHESION BIOSCIENCES LIMITED

WEB	ORDER	SUPPORT	CUSTOM
www.cohesionbio.com	order@cohesionbio.com	techsupport@cohesionbio.com	custom@cohesionbio.com



Product Data Sheet

PRAMEF9 siRNA (Human) - C	5 nmol x 1	5 nmol x 2	
Negative Control	2.5 nmol x 1	2.5 nmol x 2	
DEPC Water	1 ml x 1	1 ml x 2	

Directions for Use

We recommends transfection with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For example, resuspend one tube of 5 nmol siRNA oligo in 250 μ l of DEPC water to get a final concentration of 20 μ M.

Plate	Final volume	Final concentration	siRNA (20 μM)	Lipofectamin
	of medium	of siRNA		2000
		100 nM	0.5 μl	0.25 μl
96-well	100 µl	50 nM	0.25 μl	0.25 μl
		10 nM	0.05 μl	0.25 μl
		100 nM	2.5 μl	1 µl
24-well	500 μl	50 nM	1.25 μl	1 µl
		10 nM	0.25 μl	1 µl
		100 nM	5 µl	2 µl
12-well	1 ml	50 nM	2.5 μl	2 µl
		10 nM	0.5 μl	2 µl
6-well	2 ml	100 nM	10 µl	5 µl
		50 nM	5 μl	5 μl
		10 nM	1 µl	5 µl

Storage/Stability

Shipped at 4 °C. Store at -20 °C for one year.

Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC-Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb-Rabbit, S- Sheep, Z- Zebrafish

COHESION BIOSCIENCES LIMITED

WEB	ORDER	SUPPORT	CUSTOM
www.cohesionbio.com	order@cohesionbio.com	techsupport@cohesionbio.com	custom@cohesionbio.com